Previous research has demonstrated that signatures based on the TNF family can serve as effective prognostic tools and predict the response to immunotherapy and chemotherapy in various cancers, such as lung adenocarcinoma (LUAD) and colorectal cancer [5, 6]. This evidence concerns the gene TNF and lung adenocarcinoma.